Enjaymo (sutimlimab-jome) rapidly and sustainably reduces red blood cell destruction and the need for blood transfusions in most adults with hard-to-treat cold agglutinin disease (CAD) in real-world clinical settings, a study showed. “[Enjaymo] demonstrated rapid, durable effectiveness and a favorable safety profile in heavily pretreated real-world CAD patients,”…
Primary cold agglutinin disease (CAD) is not a single, uniform disease and can be difficult to distinguish from certain blood cancers, making it challenging to diagnose using standard criteria, a study in Japan suggests. Researchers found that, even after excluding cases linked to underlying conditions — known as cold…
Discussion
My husband, Mike, and I started our stewardship of the family home in 2004. Mom had died earlier that year and Dad wanted to provide a home for his wandering child. The house was stuffed with family treasures. Since Mom had been a hoarder in her latter years, there was…
Discussion
Sunday is my favorite day of the week. I enjoy getting together with like-minded believers to worship God. The teaching from the Bible, the sermon, is the best part, although standing to sing praises to the triune God brings a sublime joy to my heart. However, cold agglutinin disease…
A single dose of the cell therapy candidate zorpocabtagene-autoleucel (zorpo-cel) led to rapid, durable symptom relief in a woman with severe, hard-to-treat cold agglutinin disease (CAD) in a rare combination with two other autoimmune disorders, a case study reported. The woman had been dependent on blood transfusions for…
Cold agglutinin disease (CAD) is a rare disorder in which the immune system mistakenly attacks red blood cells, resulting in anemia.
CAD is characterized by autoantibodies, called cold agglutinins, binding to and activating the destruction of red blood cells when exposed to cold temperatures.
Symptoms of CAD include fatigue, Raynaud’s syndrome, joint pain, jaundice or skin discoloration, and heart problems. These symptoms can worsen with more cold exposure.
Get regular updates to your inbox.
